160801-73-0

Basic information

• Product Name: carbonyl]butyl]-, 1,1-dimethylethylester
• Synonyms: Carbamicacid, N-[(1S)-1-[(methoxymethylamino);carbonyl]butyl]-, 1,1-dimethylethylester
• CAS NO: 160801-73-0
• Molecular Formula: C₁₂H₂₄N₂O₄
• Molecular Weight: 260.32996
• Mol File: 160801-73-0.mol
• Article Data: 24

Chemical Properties

• Appearance: /
• CAS DataBase Reference: carbonyl]butyl]-, 1,1-dimethylethylester(CAS DataBase Reference)
• NIST Chemistry Reference: carbonyl]butyl]-, 1,1-dimethylethylester(160801-73-0)
• EPA Substance Registry System: carbonyl]butyl]-, 1,1-dimethylethylester(160801-73-0)

Safety Data

• Hazardous Substances Data: 160801-73-0(Hazardous Substances Data)

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 53308-95-5 N-tert-butoxycarbonyl-L-norvaline 

Downstream Products

• 856707-38-5 acetic acid (2S)-2-tert-butoxycarbonylamino-1-cyclopropylcarbamoylpentyl ester 
• 850252-34-5 (3S)-3-amino-N-cyclopropyl-2-hydroxyhexanamide hydrochloride 
• 1034154-46-5 (S)-tert-butyl 1-oxo-1-phenylpentan-2-ylcarbamate 
• 160801-88-7 Boc-Phe-Leu-Nva-CONH-CH₂CH₃ 
• 160868-27-9 Boc-D-Phe-Leu-Nva-CONH-CH₂CH₃ 
• 209398-26-5 (3S)-3-(tert-butoxycarbonylamino)-2-hydroxyhexanoic acid 
• 402959-32-4 (S)-3-Amino-2-hydroxy-hexanoic acid 
• 160801-74-1 (2S)-2-(1,1-dimethylethoxycarbonylamino)pentanal 

Relevant articles and documents

Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors

The Plasmodium proteasome is an emerging antimalarial target due to its essential role in all the major life cycle stages of the parasite and its contribution to the establishment of resistance to artemisinin (ART)-based therapies. However, because of a similarly essential role for the host proteasome, the key property of any antiproteasome therapeutic is selectivity. Several parasite-specific proteasome inhibitors have recently been reported, however, their selectivity must be improved to enable clinical development. Here we describe screening of diverse libraries of non-natural synthetic fluorogenic substrates to identify determinants at multiple positions on the substrate that produce enhanced selectivity. We find that selection of an optimal electrophilic "warhead" is essential to enable high selectivity that is driven by the peptide binding elements on the inhibitor. We also find that host cell toxicity is dictated by the extent of coinhibition of the human β2 and β5 subunits. Using this information, we identify compounds with over 3 orders of magnitude selectivity for the parasite enzyme. Optimization of the pharmacological properties resulted in molecules that retained high potency and selectivity, were soluble, sufficiently metabolically stable and orally bioavailable. These molecules are highly synergistic with ART and can clear parasites in a mouse model of infection, making them promising leads as antimalarial drugs.

INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS

Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments

HCV INHIBITORS

The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.